Muna Bhanji - 28 Apr 2022 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: Director
Signature: /s/ James Basta, Attorney-in-Fact
Issuer symbol: NTLA
Transactions as of: 28 Apr 2022
Net transactions value: $0
Form type: 4
Filing time: 02 May 2022, 21:49:32 UTC
Previous filing: 01 Apr 2022
Next filing: 11 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Award	$0	+7,954		$0.000000	7,954	28 Apr 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NTLA	Stock Option (Right to Buy)	Award	$0	+11,700		$0.000000	11,700	28 Apr 2022	Common Stock	11,700	$50.29	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2	This option was granted on April 28, 2022 with respect to 11,700 shares of Common Stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan, with 33 1/3 % vesting on April 28, 2023 and the remaining 66 2/3% vesting in 8 substantially equal quarterly installments thereafter.